CA
NZ
UK
AU
IND
US
…
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Surrozen Inc is a clinical-stage biotech developing therapeutics that modulate the Wnt signaling pathway to promote tissue regeneration. Long-term growth drivers include clinical trial progress, partnerships using its antibody platform and unmet need for regenerative treatments. Investors may find the company attractive for its focused platform and potential for durable clinical benefits if trials succeed.
Key risks are clinical and regulatory failure, limited or no product revenue requiring additional financing, strong competition from other regenerative approaches and execution risk in advancing programs.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -242.03M | -63.56M | -43.04M | -36.00M | -54.65M |
| Net income | -242.03M | -63.56M | -43.04M | -27.67M | -52.51M |
| Selling general administrative | 16.20M | 15.06M | 15.80M | 19.83M | 14.21M |
| Gross profit | 2.94M | 10.65M | -27.23M | 12.50M | - |
| Reconciled depreciation | 0.54M | 1.44M | 1.94M | 1.96M | 2.07M |
| Ebit | -242.03M | -63.56M | -43.04M | -46.29M | -56.46M |
| Ebitda | -241.49M | -62.12M | -41.13M | -44.34M | -54.39M |
| Depreciation and amortization | 0.54M | 1.44M | 1.91M | 1.96M | 2.07M |
| Operating income | -42.09M | -25.54M | -45.78M | -44.34M | -54.39M |
| Other operating expenses | 45.57M | 36.19M | 45.78M | 56.84M | 54.39M |
| Interest expense | - | - | - | 1.96M | 2.07M |
| Interest income | 3.02M | 1.69M | 2.31M | 0.78M | 0.07M |
| Net interest income | 3.02M | 1.69M | 2.31M | 0.78M | 0.07M |
| Income tax expense | - | -63.56M | 2.75M | -8.34M | -2.14M |
| Total revenue | 3.48M | 10.65M | 12.50M | 12.50M | 0.00M |
| Total operating expenses | 45.03M | 36.19M | 18.55M | 56.84M | 54.39M |
| Cost of revenue | 0.54M | 1.44M | 27.23M | - | - |
| Total other income expense net | -199.93M | -38.02M | 2.74M | 8.34M | -0.26M |
| Net income from continuing ops | -242.03M | -63.56M | -34.90M | -36.00M | -54.65M |
| Net income applicable to common shares | - | - | - | - | -54.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 98.73M | 48.47M | 46.08M | 89.44M | 137.17M |
| Other current assets | 2.11M | 1.83M | 2.94M | 3.49M | 3.34M |
| Total liab | 286.49M | 69.85M | 8.14M | 13.43M | 27.47M |
| Total stockholder equity | -187.76M | -21.38M | 37.94M | 76.00M | 109.70M |
| Other current liab | 7.91M | 5.18M | 4.13M | 6.85M | 0.59M |
| Common stock | 0.00M | - | - | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -527.28M | -285.26M | -221.69M | -178.65M | -142.65M |
| Other liab | - | - | - | - | 8.30M |
| Other assets | - | - | - | - | 0.95M |
| Cash | 89.25M | 34.56M | 36.04M | 24.69M | 33.09M |
| Total current liabilities | 9.93M | 7.32M | 7.15M | 9.73M | 13.57M |
| Current deferred revenue | - | - | - | - | 8.07M |
| Net debt | -82.61M | -26.10M | -32.66M | -19.09M | -25.30M |
| Short term debt | 1.29M | 1.83M | 2.50M | 2.23M | 2.19M |
| Short long term debt total | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Other stockholder equity | 339.52M | 263.88M | 259.63M | 254.89M | 252.46M |
| Property plant equipment | - | - | - | - | 9.38M |
| Total current assets | 91.56M | 38.93M | 41.13M | 81.31M | 105.19M |
| Long term investments | - | - | - | 0.00M | 21.66M |
| Net tangible assets | - | - | - | - | 109.70M |
| Short term investments | - | - | 0.00M | 51.15M | 68.76M |
| Net receivables | 0.21M | 2.54M | 2.15M | 1.98M | - |
| Inventory | - | - | 0.00M | - | - |
| Accounts payable | 0.73M | 0.31M | 0.53M | 0.66M | 2.72M |
| Accumulated other comprehensive income | - | - | - | -0.24M | -0.12M |
| Non currrent assets other | 0.05M | 1.17M | 0.40M | 1.23M | 0.95M |
| Non current assets total | 7.17M | 9.54M | 4.95M | 8.13M | 31.98M |
| Capital lease obligations | 6.64M | 8.47M | 3.38M | 5.60M | 7.79M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.03M | 44.14M | 38.31M | -77.71M |
| Change to liabilities | - | - | - | - | 0.86M |
| Total cashflows from investing activities | -0.13M | -0.03M | 51.72M | - | -77.71M |
| Total cash from financing activities | 85.05M | 16.18M | 0.28M | -2.56M | 124.63M |
| Change to operating activities | - | - | - | - | -1.08M |
| Net income | -242.03M | -63.56M | -43.04M | -36.00M | -54.65M |
| Change in cash | 54.68M | -1.48M | 11.64M | -8.40M | -1.89M |
| Begin period cash flow | 35.25M | 36.73M | 25.09M | 33.50M | 35.39M |
| End period cash flow | 89.93M | 35.25M | 36.73M | 25.09M | 33.50M |
| Total cash from operating activities | -30.24M | -17.63M | -40.36M | -44.15M | -48.81M |
| Issuance of capital stock | 83.78M | 16.04M | 0.00M | 0.00M | 124.22M |
| Depreciation | 0.54M | 1.44M | 1.91M | 1.96M | 2.07M |
| Change to account receivables | 2.33M | -0.50M | 0.00M | -1.98M | - |
| Sale purchase of stock | 0.20M | 0.09M | -0.00M | -2.61M | - |
| Other cashflows from financing activities | 85.05M | 0.13M | 0.28M | 0.04M | 0.41M |
| Change to netincome | - | - | - | - | 3.99M |
| Capital expenditures | 0.13M | 0.03M | 0.40M | 0.73M | 1.27M |
| Change in working capital | 3.15M | -0.84M | -3.93M | -8.42M | -0.22M |
| Stock based compensation | 3.83M | 4.11M | 4.37M | 4.52M | 2.32M |
| Other non cash items | 204.26M | 41.22M | 0.33M | -6.20M | 1.23M |
| Free cash flow | -30.37M | -17.65M | -40.76M | -44.87M | -50.08M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| SRZN Surrozen Inc |
1.00 3.23% |
32.00 | - | - | 18.14 | 2.50 | 9.87 | 0.71 |
| NVO Novo Nordisk A/S |
1.09 2.72% |
41.41 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
3.78 0.69% |
550.87 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
15.61 1.73% |
919.96 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
650 489 9000
44
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig C. Parker M.B.A. | CEO, Pres & Director | 1962 |
| Mr. Charles Williams | Chief Financial Officer | 1980 |
| Dr. Wen-Chen Yeh M.D., Ph.D. | Chief Scientific Officer | 1964 |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisor | NA |
| Dr. Roeland Nusse Ph.D. | Co-Founder & Member of Scientific Advisor | 1950 |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder & Member of Scientific Advisor | NA |
| Ms. Sheela Mohan-Peterson J.D., M.S. | Sr. VP of Legal, Gen. Counsel & Corp. Sec. | 1962 |
| Dr. Geertrui Vanhove M.B.A., M.D., Ph.D. | Chief Medical Officer | 1966 |
| Dr. Li Yang Ph.D. | Sr. VP of Biology | NA |
| Ms. Elizabeth Nguyen | Sr. VP and Head of Talent & Culture | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.88%
Communication Services
+1.14%
Consumer Cyclical
+1.04%
Consumer Defensive
+0.57%
Energy
+0.50%
Financial Services
+0.81%
Financials
+0.24%
Healthcare
+1.35%
Industrials
+1.54%
Real Estate
+0.24%
Technology
+2.32%
Utilities
+0.48%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
-4.40%
Please wait processing your request...